Global Diabetes Care Devices Market Outlook
Revenue, 2024
$31.2B
Forecast, 2034
$106B
CAGR, 2025 - 2034
13.1%
The Diabetes Care Devices industry revenue is expected to be around $35.3 billion in 2025 and expected to showcase growth with 13.1% CAGR between 2025 and 2034. The market shows strong potential because diabetes care devices play an essential part in contemporary chronic disease treatment as diabetes cases increase and people live longer and develop health issues through their lifestyle choices. The market depends on blood glucose monitoring systems which produced $17.6 billion in revenue during 2024 to support medical choices for patients with 1 and 2 diabetes. The market depends on Self/Home Healthcare and Hospitals & Diabetes Specialty Clinics for 100.0% of its end user adoption because these segments focus on patient empowerment through home healthcare and clinical workflow optimization.
The portfolio of diabetes care devices includes blood glucose meters and test strips and continuous glucose monitoring systems and insulin pumps and smart insulin pens and digital diabetes management solutions which provide real time glycemic status information. The main characteristics of top solutions include precise measurement capabilities and simple operation systems and compact designs and wireless connectivity to smartphones and cloud systems for patient data exchange. The main uses of these devices include home blood glucose testing and hospital glucose management and pregnancy diabetes treatment and insulin dose adjustment for advanced therapy plans. The market for diabetes care devices experiences changing demands because people now use wearable sensors more frequently and AI based analytics for individualized treatment and devices that link to digital platforms for data driven diabetes management throughout the entire care process.
Market Key Insights
The Diabetes Care Devices market will expand from $31.2 billion in 2024 to reach $107 billion by 2034. The market will expand at a 13.1% annual rate because people need these devices more for Home Healthcare and Hospital Care and Diabetes Clinics.
F. Hoffmann-La Roche, Abbott, and Medtronic are among the leading players in this market, shaping its competitive landscape.
The Diabetes Care Devices market shows the United States and China as its leading markets which will experience 11.8% to 15.7% annual growth rates from 2024 to 2030.
The market research predicts that Indonesia along with Brazil and Indonesia will experience the highest growth rate at 9.2% to 13.8% CAGR.
Transition like Diabetes Devices Become Connected is expected to add $8 billion to the Diabetes Care Devices market growth by 2030
.The Diabetes Care Devices market will experience $75.7 billion growth during 2024-2034 because Hospitals & Diabetes Specialty Clinics Application will dominate market expansion.
With
rising global diabetes prevalence and growing emphasis on home-based monitoring accelerating adoption of diabetes care devices, and
Rapid integration of connected digital health ecosystems enhancing real-time data insights from diabetes care devices, Diabetes Care Devices market to expand 242% between 2024 and 2034.
Opportunities in the Diabetes Care Devices
The global blood glucose monitoring systems market generated USD 17.6 billion in 2024 and experts predict it will reach USD 34.18 billion by 2030 but these products have also not only gained popularity among Asian Pacific tech oriented urban millennials. The combination of continuous and flash glucose monitors with smartphone integration helps people manage their 2 diabetes and prediabetes conditions. The connected CGM subsegments will experience the most rapid expansion because they integrate app based coaching with gamified adherence and telemedicine platform and fitness ecosystem and employer wellness program partnerships.
Growth Opportunities in North America and Asia-Pacific
The Self/Home Healthcare end user segment in North America shows the highest adoption rate for diabetes care devices because patients are well informed about their condition and the healthcare system provides complete payment coverage and supports advanced digital technology for home based insulin delivery systems and continuous glucose monitoring systems and connected glucometers; the market offers excellent prospects for device software integration and data based adherence systems and payor and retail pharmacy collaboration; multinational companies lead the market but digital health startups challenge their position through their agile approach and user focused strategies and electronic health record integration and analytical capabilities.
The Hospital & Diabetes Specialty Clinic sector stands as the leading end user for diabetes care devices throughout Asia Pacific because these institutions control both diagnosis and extended treatment of diabetes across various markets which creates major business potential for hospital grade blood glucose monitors and integrated insulin delivery systems and large scale device deployments in public facilities. The Self/Home Healthcare market segment shows increasing popularity because urban residents who have middle class status want easy to use monitoring devices with mobile application support for their healthcare needs. The North American market shows less competition between multinational brands and regional manufacturers who focus on cost and domestic champions who use their local distribution networks and government contracts and customized support services to compete. The main factors driving regional growth stem from urban diabetes cases rising due to modern living habits and improved healthcare access and government health programs and digital health platform investments which bring specialist care to communities and homes.
Market Dynamics and Supply Chain
01
Driver: Rising global diabetes prevalence and growing emphasis on home based monitoring accelerating adoption of diabetes care devices
The increasing number of people with diabetes worldwide also creates new opportunities to treat patients through advanced blood glucose monitoring systems and insulin delivery devices which serve both 1 and 2 diabetes patients. The combination of aging populations and sedentary living and urbanization trends leads to higher diabetes diagnosis numbers in developing countries which also drives healthcare systems to adopt continuous glucose monitoring systems and smart insulin pens for better glycemic control and reduced hospital expenses. The home based monitoring trend has also led manufacturers to create smaller connected glucose meters and wearable diabetes technology and user friendly lancet free solutions which match everyday activities. The new monitoring system allows healthcare providers to monitor patients data in real time for therapy adjustments through remote programs. Manufacturers now develop diabetes care devices which operate as interconnected systems to enable digital platform integration for personalized dosing recommendations and better home treatment compliance.
The fast adoption of connected digital health systems now changes how diabetes care devices handle clinical data through their data generation and sharing and utilization processes. The integration of continuous glucose monitoring systems with insulin pumps and smart insulin pens now allows medical staff to access electronic health records for better long term pattern analysis and treatment optimization. The AI based analytics systems in these ecosystems detect hypoglycemia threats while generating insulin dosage recommendations and supporting healthcare programs for population management. The combination of connected diabetes care devices with telehealth platforms and remote coaching enables healthcare providers to perform data based proactive interventions which enhance patient involvement and lead to better blood sugar control with fewer clinic visits.
02
Restraint: High upfront costs and limited reimbursement slow adoption of advanced diabetes care devices globally
The high initial costs of premium diabetes care devices including continuous glucose monitoring and advanced insulin delivery systems along with insufficient insurance coverage leads patients and providers to delay their purchases which results in increased sales of less expensive blood glucose monitoring systems that lower market prices and limit business expansion into new markets with limited budget capacity.
03
Opportunity: AI driven diabetes management mobile applications for multimorbid elderly patients within European national e health systems and Advanced wearable insulin pumps and smart pens for under treated 2 diabetics in Latin America
The market for diabetes management mobile applications shows the fastest growth because it will expand from USD 3.37 billion in 2024 to USD 9.59 billion by 2030 at a 19.05% annual growth rate. The European market demands integrated reimbursable apps that connect to e health records because its aging population has multiple chronic conditions. The market will experience its highest expansion through regulated AI based platforms which unite glucose monitoring with medication alerts and cardiometabolic risk notification systems. The platforms will achieve large scale deployment through hospital and EHR vendor and public health insurer partnerships for strategic development.
The market for insulin delivery devices will expand from USD 10.23 billion in 2024 to USD 21.53 billion by 2030 at a 13.2% annual growth rate. The adoption of pump and smart pen devices remains minimal in Latin American primary care facilities. Manufacturers should create affordable patch pumps and Bluetooth enabled pens for public clinics that need simple devices. The market will experience its most significant expansion through interoperable devices which run titration algorithms while manufacturers establish partnerships with local distributors and payers and diabetes education programs that focus on 2 patients.
04
Challenge: Data privacy concerns and interoperability gaps restrict integration of connected diabetes care devices into workflows
Healthcare facilities avoid complete adoption of connected diabetes care devices and remote patient monitoring solutions and digital health platforms because device data fails to connect properly with their current clinical systems and because they perceive high cybersecurity and privacy threats which reduces market interest in advanced connectivity features and restricts data service subscriptions and creates market fragmentation between hardware and software and service segments.
Supply Chain Landscape
1
Glucose Sensor Components
Dexcom Inc.AbbottMedtronic
2
Diabetes Care Devices
F. Hoffmann-La Roche Ltd.MedtronicB. Braun SE
3
Insulin Delivery Logistics
AbbottF. Hoffmann-La Roche Ltd.B. Braun SE
4
End-User
Hospitals & ClinicsHome HealthcareDiagnostic Centers
1
Glucose Sensor Components
Dexcom Inc.AbbottMedtronic
2
Diabetes Care Devices
F. Hoffmann-La Roche Ltd.MedtronicB. Braun SE
3
Insulin Delivery Logistics
AbbottF. Hoffmann-La Roche Ltd.B. Braun SE
4
End-User
Hospitals & ClinicsHome HealthcareDiagnostic Centers
Use Cases of Diabetes Care Devices in Home Healthcare & Clinics
Home Healthcare : The largest end user segment for diabetes care devices in self/home healthcare consists of patients who manage their condition outside clinical environments. The market generated USD 23.28 billion in 2024 and researchers predict it will expand at a 14.2% annual rate from 2025 to 2030. The market demands blood glucose monitoring systems at 56.4% for routine capillary testing and home diabetes monitoring while insulin delivery devices and diabetes management mobile applications serve more than 40% of customers for precise dosing and digital diabetes management. The market leaders Abbott and Dexcom Inc. and F. Hoffmann La Roche Ltd. maintain their positions through user friendly meters and application based systems which focus on simplicity while Medtronic and B. Braun SE concentrate on developing dependable delivery systems that merge well with self injection and home infusion practices. The home based diabetes care devices help patients follow their treatment plans better while decreasing their need for emergency care and allowing them to take control of their self management and future health results.
Hospital Care : The Hospitals & Diabetes Specialty Clinics segment which includes emergency and perioperative and intensive care units depends on diabetes care devices for tight glycemic control because these devices generate approximately USD 7.92 billion in 2024 and will expand at 9.51% CAGR until 2030. The healthcare facilities use blood glucose monitoring systems for bedside testing and automated insulin titration protocols to manage their patients. The medical facilities use advanced insulin delivery devices and insulin pumps to administer intravenous and subcutaneous insulin therapy for their most complex and critically ill patients. The high risk wards of hospitals use continuous glucose monitoring to monitor fast glucose changes which enables medical staff to take early action. The hospital diabetes management segment benefits from F. Hoffmann La Roche Ltd. and Abbott through their extensive diagnostic and point of care product lines but B. Braun SE stands out through its infusion pumps and safety focused consumables for acute care settings and Medtronic leads through its interoperable insulin therapy systems which integrate with hospital information systems and clinical decision support tools. The implementation of these diabetes care devices in hospitals enables better patient results and shorter hospital stays and reduces the chances of dangerous blood sugar levels in hospital patients through evidence based treatment protocols.
Diabetes Clinics : The main function of diabetes clinics involves extended care for complicated patients through device based connections between home and hospital environments to execute evidence based treatment protocols for different patient groups. The combination of blood glucose monitoring systems with educational programs and scheduled device data assessments enables clinicians to use advanced insulin delivery systems including pump based therapies and smart insulin pens and diabetes management mobile applications for precise treatment adjustments and continuous patient behavior tracking between appointments. The clinic focused ecosystems of Medtronic and Dexcom Inc. use their monitoring and therapy data integration to create advanced decision support software while Abbott and F. Hoffmann La Roche Ltd. expand their product range with monitoring solutions for different clinical needs and healthcare resources and B. Braun SE delivers strong delivery systems and equipment that supports complex insulin treatment and combination therapy programs. The integration of diabetes care devices enables diabetes clinics to create personalized treatment plans which lead to faster therapy improvements and better long term patient adherence and complication management for diverse patient groups.
Recent Developments
The current diabetes care devices market shows fast growth of continuous glucose monitoring systems and smart insulin pens which operate through digital health platforms. The combination of better sensor performance and wearable diabetes devices and AI based analytics enables patients to achieve better blood sugar management through individualized care. The market now focuses on connected insulin delivery systems and closed loop insulin pumps which operate through mobile health applications.
March 2024 : The U.S. FDA granted Dexcom approval to market its Stelo over the counter continuous glucose monitoring system which enables more people with 2 diabetes and other non insulin dependent conditions to access advanced diabetes management tools. The approval expands sensor based glucose monitoring capabilities for proactive disease management through its new role in adult diabetes care.
April 2023 : The FDA approved Medtronic to market its MiniMed 780G advanced hybrid closed loop insulin pump with Guardian 4 sensor which maintains their position as diabetes care leaders and enables more people to use automated insulin delivery systems and advanced insulin delivery devices.
March 2023 : The U.S. FDA granted Abbott permission to market FreeStyle Libre 2 and FreeStyle Libre 3 sensors as standalone continuous glucose monitoring systems which work with specific automated insulin delivery devices to improve device connectivity in diabetes care and increase sensor based glucose monitoring availability in home and outpatient environments.
Impact of Industry Transitions on the Diabetes Care Devices Market
As a core segment of the Medical Device industry,
the Diabetes Care Devices market develops in line with broader industry shifts.
Over recent years, transitions such as Diabetes Devices Become Connected and Home Centric, Value Based Management have redefined priorities
across the Medical Device sector,
influencing how the Diabetes Care Devices market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Diabetes Devices Become Connected
The Diabetes Care Devices market is undergoing a transformative shift towards interconnected ecosystems that integrate continuous glucose monitoring systems, insulin pumps, and mobile health applications. This transition facilitates real time data exchange between blood glucose meters, clinicians, and payers, enhancing remote patient monitoring capabilities. The incorporation of smart insulin pens and digital therapeutics, alongside AI driven diagnostic tools, is revolutionizing patient care workflows. As a result of these advancements, the Diabetes Care Devices market is projected to experience a substantial growth of $9 billion by 2030, underscoring the strategic importance of connectivity in improving patient outcomes and operational efficiencies within the healthcare landscape. This industry transition is expected to add $8 billion in the industry revenue between 2024 and 2030.
02
Home Centric, Value Based Management
The healthcare industry transition to value based care has led diabetes care devices to evolve from clinic bound tools into home based integrated systems which support hospital at home programs. The integration of continuous glucose monitoring systems and connected insulin delivery devices into electronic health records enables risk based reimbursement and population health analytics. The integration of medical sensors into wearable devices by consumer electronics brands creates a boundaryless connection between wellness tracking and clinical disease management. The healthcare industry now sees increased collaboration between different sectors because insurers and retail pharmacies and cloud providers work together to create chronic disease management platforms which use diabetes data for managing cardiometabolic risks.